A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001

Authors

Geoffrey L. Uy, Washington University School of Medicine in St. Louis
Peter Westervelt, Washington University School of Medicine in St. Louis

Journal

Blood Advances

Publication Date

2017

Volume

1

Issue

5

Inclusive Pages

331-340

Document Type

Open Access Publication

DOI

https://doi.org/10.1182/bloodadvances.2016003053

Rights and Permissions

Uy, G. L., Mandrekar, S. J., Laumann, K., Marcucci, G., Zhao, W., Levis, M. J., Klepin, H. D., Baer, M. R., Powell, B. L., Westervelt, P., DeAngelo, D. J., Stock, W., Sanford, B., Blum, W. G., Bloomfield, C. D., Stone, R. M., & Larson, R. A. (2017). A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advances, 1(5), 331-340. https://doi.org/10.1182/bloodadvances.2016003053.

Recommended Citation

Uy, Geoffrey L. and Westervelt, Peter, "A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001." Blood Advances. 1, 5. 331-340. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/7227